HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The firm's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. The firm is also engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are developed in a partnership with Gilead Sciences Inc.
How did HOOK's recent EPS compare to expectations?
The most recent EPS for HOOKIPA Pharma Inc is $, expectations of $-0.2.
How did HOOKIPA Pharma Inc HOOK's revenue perform in the last quarter?
HOOKIPA Pharma Inc revenue for the last quarter is $
What is the revenue estimate for HOOKIPA Pharma Inc?
According to of Wall street analyst, the revenue estimate of HOOKIPA Pharma Inc range from $ to $
What's the earning quality score for HOOKIPA Pharma Inc?
HOOKIPA Pharma Inc has a earning quality score of B+/56.63162. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does HOOKIPA Pharma Inc report earnings?
HOOKIPA Pharma Inc next earnings report is expected in 2026-02-10
What are HOOKIPA Pharma Inc's expected earnings?
HOOKIPA Pharma Inc expected earnings is $, according to wall-street analysts.
Did HOOKIPA Pharma Inc beat earnings expectations?
HOOKIPA Pharma Inc recent earnings of $ expectations.